Last €9.45 EUR
Change Today +0.05 / 0.53%
Volume 4.9K
ALMED On Other Exchanges
Symbol
Exchange
EN Paris
As of 6:07 AM 10/2/14 All times are local (Market data is delayed by at least 15 minutes).

medicrea international (ALMED) Snapshot

Open
€9.40
Previous Close
€9.40
Day High
€9.45
Day Low
€9.38
52 Week High
06/6/14 - €10.60
52 Week Low
01/13/14 - €7.05
Market Cap
80.1M
Average Volume 10 Days
3.4K
EPS TTM
€0.05
Shares Outstanding
8.5M
EX-Date
--
P/E TM
201.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDICREA INTERNATIONAL (ALMED)

Related News

No related news articles were found.

medicrea international (ALMED) Related Businessweek News

No Related Businessweek News Found

medicrea international (ALMED) Details

Medicrea manufactures and distributes implants in France. It offers PASS range, a polyaxial spine system; PASS LP, a thoraco-lumbar fixation system; LigaPASS, a band connector for posterior thoracic fixation use to de-rotate and correct spinal deformities, such as scoliosis; and PASS ANT, a polyaxial low profile thoraco-lumbar system for anterior approach. The company also provides a range of implants for the cervical spine, including C-JAWS, an anterior cervical spinal fixation system; IMPIX C, a sterile PEEK Optima cervical inter body device; Impix C+, a sterile PEEK Optima cervical inter body device that is prefilled with bone substitutes; and MANTA, a sterile PEEK Optima cervical inter body device, which is preassembled on holder and delivers with disposable instrumentation kit. Its implants for cervical spine also include MANTA +, a sterile PEEK Optima cervical inter body device, which is prefilled with bone substitutes, as well as preassembled on disposable holder and delivered with disposable instrumentation kit; GRANVIA C, a MRI compatible ceramic cervical disc; and LaminoJAWS, a cervical laminoplasty implant with a posterior approach. In addition, the company offers implants for the thoracic and lumbar spine, such as IMPIX-L, a sterile PEEK Optima lumbar inter body device for posterior approach; IMPIX ALIF, a sterile PEEK Optima lumbar inter body device for anterior approach; and OSMOSYS, a macro porous bone substitute. Its implants are designed to treat scoliosis, degenerative deformation, trauma, and tumors; and are used in various traditional and advanced surgical techniques, such as minimally-invasive surgery. The company was founded in 1990 and is based in Lyon, France.

109 Employees
Last Reported Date: 04/25/14
Founded in 1990

medicrea international (ALMED) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

medicrea international (ALMED) Key Developments

The MEDICREA Group Obtains FDA Approval for its Marketing in the United States

The MEDICREA Group announced that the FDA has approved the K-JAWS Cervical Compression Staple for all cervical fixation indications carried out with interbody cages. This breakthrough innovation targets an American cervical fixation market estimated at $1.2 billion that is occupied by relatively homogenous cervical plate and standalone cage ranges that differ little from each other. The K-JAWS implant is considerably less invasive and much quicker to insert than any cervical plate currently on the market. Its principle, which consists in fixing two adjacent vertebra by compression around a previously-inserted interbody cage, results in exceptional stability due to the axial localization of the compression forces, at the level of the spine's vertebral bodies.

Medicrea Presents at CF&B 14th Large & Midcap Event, Oct-02-2014

Medicrea Presents at CF&B 14th Large & Midcap Event, Oct-02-2014 . Venue: Palais Brongni, 28 Place de la Bourse, entrée Rue Vivienne, 75002 Paris, France.

The MEDICREA Group Announces Sales Results for the First Half of the Fiscal Year Ended June 30, 2014

The MEDICREA Group announced sales results for the first half of the fiscal year ended June 30, 2014. For the period, the company reported sales of EUR 11.9 million compared to EUR 11.9 million a year ago. The group recorded a significant increase in its sales in the United States, its priority development market. In dollars, U.S. sales increased 18% compared with the first half of 2013, with a new monthly invoicing record of $2.4 million in June. As of June 30, 2014, U.S. sales accounted for 56% of the group's total sales.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALMED:FP €9.45 EUR +0.05

ALMED Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALMED.
View Industry Companies
 

Industry Analysis

ALMED

Industry Average

Valuation ALMED Industry Range
Price/Earnings 100.0x
Price/Sales 3.1x
Price/Book 5.5x
Price/Cash Flow 153.5x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDICREA INTERNATIONAL, please visit www.medicrea.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.